What pulmonologists think about the asthma–COPD overlap syndrome

Marc Miravitlles; Bernardino Alcázar; Francisco Javier Alvarez; Teresa Bazús; Myriam Calle; Ciro Casanova; Carolina Cisneros; Juan P. De-Torres; Luis M. Entrenas; Cristóbal Esteban; Patricia García-Sidro; Borja G. Cosio; Arturo Huerta; Milagros Iriberri; José Luis Izquierdo; Antolín López-Viña; José Luis López-Campos; Eva Martínez-Moragón; Luis Pérez de Llano; Miguel Perpiñá; José Antonio Ros; José Serrano; Juan José Soler-Cataluña; Alfons Torrego; Isabel Urrutia; Vicente Plaza

doi:https://doi.org/10.2147/COPD.S88667

What pulmonologists think about the asthma–COPD overlap syndrome

Marc Miravitlles, Bernardino Alcázar, Francisco Javier Alvarez, Teresa Bazús, Myriam Calle, Ciro Casanova, Carolina Cisneros, Juan P. De-Torres, Luis M. Entrenas, Cristóbal Esteban, Patricia García-Sidro, Borja G. Cosio, Arturo Huerta, Milagros Iriberri, José Luis Izquierdo, Antolín López-Viña, José Luis López-Campos, Eva Martínez-Moragón, Luis Pérez de Llano, Miguel PerpiñáJosé Antonio Ros, José Serrano, Juan José Soler-Cataluña, Alfons Torrego, Isabel Urrutia, Vicente Plaza

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

28 Citations (Scopus)

Abstract

© 2015, Miravitlles et al. Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma–COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity <0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids.

Original language	English
Pages (from-to)	1321-1330
Journal	International Journal of COPD
Volume	10
DOIs	https://doi.org/10.2147/COPD.S88667
Publication status	Published - 15 Jul 2015

Keywords

ACOS
Asthma
COPD
Guidelines
Survey

Access to Document

https://doi.org/10.2147/COPD.S88667

https://ddd.uab.cat/record/185395

Cite this

Miravitlles, M., Alcázar, B., Alvarez, F. J., Bazús, T., Calle, M., Casanova, C., Cisneros, C., De-Torres, J. P., Entrenas, L. M., Esteban, C., García-Sidro, P., Cosio, B. G., Huerta, A., Iriberri, M., Izquierdo, J. L., López-Viña, A., López-Campos, J. L., Martínez-Moragón, E., de Llano, L. P., ... Plaza, V. (2015). What pulmonologists think about the asthma–COPD overlap syndrome. International Journal of COPD, 10, 1321-1330. https://doi.org/10.2147/COPD.S88667

@article{2a18f54d58ee40ab80f0903b6ab90d73,

title = "What pulmonologists think about the asthma–COPD overlap syndrome",

abstract = "{\textcopyright} 2015, Miravitlles et al. Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma–COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity <0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids.",

keywords = "ACOS, Asthma, COPD, Guidelines, Survey",

author = "Marc Miravitlles and Bernardino Alc{\'a}zar and Alvarez, {Francisco Javier} and Teresa Baz{\'u}s and Myriam Calle and Ciro Casanova and Carolina Cisneros and De-Torres, {Juan P.} and Entrenas, {Luis M.} and Crist{\'o}bal Esteban and Patricia Garc{\'i}a-Sidro and Cosio, {Borja G.} and Arturo Huerta and Milagros Iriberri and Izquierdo, {Jos{\'e} Luis} and Antol{\'i}n L{\'o}pez-Vi{\~n}a and L{\'o}pez-Campos, {Jos{\'e} Luis} and Eva Mart{\'i}nez-Morag{\'o}n and {de Llano}, {Luis P{\'e}rez} and Miguel Perpi{\~n}{\'a} and Ros, {Jos{\'e} Antonio} and Jos{\'e} Serrano and Soler-Catalu{\~n}a, {Juan Jos{\'e}} and Alfons Torrego and Isabel Urrutia and Vicente Plaza",

year = "2015",

month = jul,

day = "15",

doi = "https://doi.org/10.2147/COPD.S88667",

language = "English",

volume = "10",

pages = "1321--1330",

}

Miravitlles, M, Alcázar, B, Alvarez, FJ, Bazús, T, Calle, M, Casanova, C, Cisneros, C, De-Torres, JP, Entrenas, LM, Esteban, C, García-Sidro, P, Cosio, BG, Huerta, A, Iriberri, M, Izquierdo, JL, López-Viña, A, López-Campos, JL, Martínez-Moragón, E, de Llano, LP, Perpiñá, M, Ros, JA, Serrano, J, Soler-Cataluña, JJ, Torrego, A, Urrutia, I & Plaza, V 2015, 'What pulmonologists think about the asthma–COPD overlap syndrome', International Journal of COPD, vol. 10, pp. 1321-1330. https://doi.org/10.2147/COPD.S88667

TY - JOUR

T1 - What pulmonologists think about the asthma–COPD overlap syndrome

AU - Miravitlles, Marc

AU - Alcázar, Bernardino

AU - Alvarez, Francisco Javier

AU - Bazús, Teresa

AU - Calle, Myriam

AU - Casanova, Ciro

AU - Cisneros, Carolina

AU - De-Torres, Juan P.

AU - Entrenas, Luis M.

AU - Esteban, Cristóbal

AU - García-Sidro, Patricia

AU - Cosio, Borja G.

AU - Huerta, Arturo

AU - Iriberri, Milagros

AU - Izquierdo, José Luis

AU - López-Viña, Antolín

AU - López-Campos, José Luis

AU - Martínez-Moragón, Eva

AU - de Llano, Luis Pérez

AU - Perpiñá, Miguel

AU - Ros, José Antonio

AU - Serrano, José

AU - Soler-Cataluña, Juan José

AU - Torrego, Alfons

AU - Urrutia, Isabel

AU - Plaza, Vicente

PY - 2015/7/15

Y1 - 2015/7/15

N2 - © 2015, Miravitlles et al. Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma–COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity <0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids.

AB - © 2015, Miravitlles et al. Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma–COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity <0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting β2-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting β2-agonist/inhaled corticosteroids.

KW - ACOS

KW - Asthma

KW - COPD

KW - Guidelines

KW - Survey

U2 - https://doi.org/10.2147/COPD.S88667

DO - https://doi.org/10.2147/COPD.S88667

M3 - Article

VL - 10

SP - 1321

EP - 1330

ER -

What pulmonologists think about the asthma–COPD overlap syndrome

Abstract

Keywords

Access to Document

Fingerprint

Cite this